Response Genetics, Inc. (RGDX.W)

RGDX.W on CBOE When Trading NASDAQ Global Select Market

1.39USD
21 Jan 2010
Price Change (% chg)

$0.04 (+3.12%)
Prev Close
$1.39
Open
--
Day's High
$1.32
Day's Low
$1.26
Volume
2,700
Avg. Vol
7,010
52-wk High
$2.72
52-wk Low
$0.29

RGDX.W

Chart for RGDX.W

About

Response Genetics, Inc. is engaged in the research and development of clinical diagnostic tests for cancer based on its technologies. The Company generates revenues primarily from sales of its analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. During the fiscal year ended... (more)

Overall

Beta: 0.30
Market Cap (Mil.): $20.19
Shares Outstanding (Mil.): 15.30
Annual Dividend: 0.00
Yield (%): NA

Financials

  RGDX.W Industry Sector
P/E (TTM): -- 1.96 3.76
EPS (TTM): -40.42 -- --
ROI: -105.04 0.92 2.30
ROE: -136.03 1.27 2.82
view overview for:

Latest News about RGDX.W

US-RESEARCH/ (NON-S&P500)

Par Pharmaceutical Caris Raises to above average from average --------------------------------------------------------------- ------------ Petrominerales Ltd CIBC Raises to sector outperformer from sector performer --------------------------------------------------------------- ------------ PNM Resources RBC Cuts to sector perform from

13 Aug 2008

Response Genetics Inc Q3 results

RESPONSE GENETICS INC : * Third quarter loss per share $0.09 * Third quarter revenue rose 24 percent to $2.2 million * Reuters Estimates third quarter earnings per share view $-0.18, revenue view $1.54 million

14 Nov 2007

TABLE-Response Genetics Q2 net loss widens

RESPONSE GENETICS INC. (in $) Latest Yr-ago qtr Loss/shr (diluted) 0.58 0.36 Net loss to common shareholders (thousands) 2,663 981 Net loss (thousands) 2,484 747 Revenue (thousands) 1,496 738 Reuters Estimates: Revenue $1.6 million (one analyst) (Reporting by Jennifer Robin Raj in Bangalore)

14 Aug 2007
» More RGDX.W News

Competitors

  Price Change
Genomic Health, Inc. (GHDX.OQ) $17.18 +0.24
Clinical Data, Inc. (CLDA.OQ) $15.37 +0.58

  Earnings  vs    Estimates

view overview for: